Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-&#945; activity restored are at risk of developing hepatic tumors.

Kim, Goo-Young; Lee, Young Mok; Kwon, Joon Hyun; Cho, Jun-Ho; Pan, Chi-Jiunn; Starost, Matthew F; Mansfield, Brian C; Chou, Janice Y

Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-α activity restored are at risk of developing hepatic tumors.

Kim, Goo-Young; Lee, Young Mok; Kwon, Joon Hyun; Cho, Jun-Ho; Pan, Chi-Jiunn; Starost, Matthew F; Mansfield, Brian C; Chou, Janice Y.

Afiliação

Kim GY; Section on Cellular Differentiation, Eunice Kennedy Shriver National Institute of Child Health and Human Development, United States.
Lee YM; Section on Cellular Differentiation, Eunice Kennedy Shriver National Institute of Child Health and Human Development, United States.
Kwon JH; Section on Cellular Differentiation, Eunice Kennedy Shriver National Institute of Child Health and Human Development, United States.
Cho JH; Section on Cellular Differentiation, Eunice Kennedy Shriver National Institute of Child Health and Human Development, United States.
Pan CJ; Section on Cellular Differentiation, Eunice Kennedy Shriver National Institute of Child Health and Human Development, United States.
Starost MF; Division of Veterinary Resources, National Institutes of Health, Bethesda, MD 20892, United States.
Mansfield BC; Section on Cellular Differentiation, Eunice Kennedy Shriver National Institute of Child Health and Human Development, United States; Foundation Fighting Blindness, Columbia, MD 21046, United States.
Chou JY; Section on Cellular Differentiation, Eunice Kennedy Shriver National Institute of Child Health and Human Development, United States. Electronic address: chouja@mail.nih.gov.

Mol Genet Metab ; 120(3): 229-234, 2017 03.

Article em En | MEDLINE | ID: mdl-28096054

Assuntos

Adenoma de Células Hepáticas/prevenção & controle; Carcinoma Hepatocelular/prevenção & controle; Terapia Genética/métodos; Glucose-6-Fosfatase/genética; Doença de Depósito de Glicogênio Tipo I/terapia; Neoplasias Hepáticas/prevenção & controle; Adenoma de Células Hepáticas/enzimologia; Animais; Carcinoma Hepatocelular/enzimologia; Dependovirus/genética; Modelos Animais de Doenças; Relação Dose-Resposta a Droga; Vetores Genéticos/administração & dosagem; Glucose/metabolismo; Glucose-6-Fosfatase/metabolismo; Doença de Depósito de Glicogênio Tipo I/complicações; Doença de Depósito de Glicogênio Tipo I/enzimologia; Homeostase; Humanos; Fígado/enzimologia; Neoplasias Hepáticas/enzimologia; Camundongos

Palavras-chave

Gene therapy; Hepatocellular adenoma; Hepatocellular carcinoma; Recombinant adeno-associated virus vector

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Terapia Genética / Doença de Depósito de Glicogênio Tipo I / Adenoma de Células Hepáticas / Glucose-6-Fosfatase / Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google